Saturday, October 19
- /
- EANO 2024/
- Programme/
- Saturday, October 19
- Thursday, October 17
- Friday, October 18
- Saturday, October 19
- Sunday, October 20
EANO Meeting - Saturday, October 19, 2024
Note that the programme is subject to change and will be continuously updated.
All times below refer to British Summer Time (BST).
08:00-09:00 hrs
Meet the Experts (ME04) | Adaptive Trials in Neurooncology
Chairs: tbc
ME04.1 GBM AGILE: an adaptive platform trial for glioblastoma
Tim Cloughesy, United States
ME04.2 Update on the N2M2 trial
Wolfgang Wick, Germany
ME04.3 The INSIGHT trial
Isabel Arrillaga-Romany, United States
Meet the Experts (ME05) | Early diagnosis of glioma
Chairs: tbc
ME05.1 Imaging characteristics of early glioma
Stuart Currie, United Kingdom
ME05.2 Serum metabolites identifies glioma development
Beatrice Melin, Sweden
ME05.3 Population screening in primary care using liquid biopsy
Matthew Baker, United Kingdom
Meet the Experts (ME06) | Lipid metabolism as a therapeutic target in glioblastoma
Chairs: tbc
ME06.1 Interplay between lipid synthesis and the DNA damage response in glioblastoma
Christian Badr, United States
ME06.2 Engulfment of lipid vesicles in glioblastoma cells triggers tumor invasion
Thomas Daubon, France
ME06.3 Targeting cholesterol metabolism to overcome radiation resistance in glioblastoma
Natividad Gomez-Roman, United Kingdom
09:00-09:15 hrs | BREAK
09:15-10:45 hrs
Joint EANO-SNO Session (JS05) | Translational Advances for Meningiomas
Chairs: tbc
JS05.1 Novel diagnostic and prognostic markers in the molecular classification of meningioma
Abigail Suwala, Germany
JS05.2 c-Impact in Meningioma
Felix Sahm, Germany
JS05.3 Predictive markers for treatment outcome in meningioma patients
David Raleigh, United States
JS05.4 Prognostic and therapeutic relevance of intra-tumoral heterogeneity in meningiomas
Priscilla Brastianos, United States
Oral Session (OS05) | Diagnosis, definition management, prevention, future research and radiation necrosis
Chairs: tbc
OS05.1 Definition & diagnosis of radionecrosis
Balamurugan Vellayappan, Singapore
OS05.2 Neuroimaging of radionecrosis
Marion Smits, Netherlands
OS05.3 Risk factors and preventative measures of radionecrosis
Esther Troost, Germany
OS05.4 Neurotoxicity of new systemic agents and Immunotherapy
Michael Weller, Switzerland
Keynote Session (KS03) | Breaking the walls: efforts to democratize access to clinical information
Chairs: tbc
KS03.1 Making data available
Fatima Al-Shahrour, Spain
KS03.2 Making images available
Víctor Pérez García, Spain
KS03.3 Integrating cancer research data
Carey Anders, United States
10:45-11:15 hrs | COFFEE BREAK
11:15-12:45 hrs
Oral Session (OS06) | Highlights from clinical abstracts
Chairs: tbc
Oral Session (OS07) | Highlights from preclinical abstracts
Chairs: tbc
Oral Session (OS08) | Advances in diagnosis and treatment of skull base tumors
Chairs: tbc
OS08.1 Advances in molecular classification of skull base tumors
Luca Bertero, Italy
OS08.2 The craniopharyngioma challenge: diagnostic clues for a judicious treatment
Ruth Prieto, Spain
OS08.3 Biology and systemic treatment for craniopharyngiomas
Priscilla Brastianos, United States
OS08.4 Radiosurgery and Radiotherapy of skull base tumors
Maximilian Niyazi, Germany
12:45-14:15 hrs | LUNCH BREAK
13:00-14:00 hrs
Corporate Symposia
14:15-15:45 hrs
Oral Session (OS09) | New target therapies in gliomas: TERT, ATRX, H3-K27M and TIM-3
Chairs: tbc
OS09.1 Using ATR inhibition to target malignant infiltration in glioblastoma
Joanna Birch, United Kingdom
OS09.2 Telomarese inhibition
Joe Costello, United States
OS09.3 H3-K27M mutation: PDGFR inhibitors and other treatments
Mariella Filbin, United States
OS09.4 TIM-3
Marta Alonso, Spain
Oral Session (OS10) | Symptomatic and asymptomatic brain metastasis: consensus and implications for therapy
Chairs: tbc
OS10.1 Consensus on symptomatic and asymptomatic brain metastasis
Hussein Tawbi, United States
OS10.2 Replacing corticoids for better therapeutic response?
Marike Broekman, Netherlands
OS10.3 Experimental approaches to prevent and to treat symptomatic brain metastases
Manuel Valiente, Spain
Chairs: tbc
PC02.1 Temozolomide for unmethylated glioma: Contra
Marjolein Geurts, Netherlands
PC02.2 Temozolomide for unmethylated glioma: Pro
Benedikte Hasselbalch, Denmark
PC02.3 Targeted therapy vs. Immunotherapy in glioblastoma: Targeted therapies are the future
Tobias Kessler, Germany
PC02.4 Targeted therapy vs. immunotherapy in glioblastoma: Immunotherapy is the future
Tobias Weiss, Switzerland
PC02.5 Virus therapy vs. immunotherapy/vaccination in neuro-oncology: Immunotherapy/vaccination is the future
Patrick Roth, Switzerland
PC02.6 Virus therapy vs. immunotherapy/vaccination in neuro-oncology: Virus therapy is the future
Gelareh Zadeh, Canada
15:45-16:00 hrs | BREAK
16:00-17:00 hrs
Neuro-Oncology Unplugged (PD01) | A historic view on glioblastoma therapy - 30 years of EANO
Chairs: tbc
PD01.1 A historical view on glioblastoma therapy
Michael Weller, Switzerland
PD01.2 A historical view on glioblastoma therapy
Susan Chang, United States
Joint EANO-EANM Session (JS06) | Therapy of meningioma
Chairs: tbc
JS06.1 Imaging challenges of meningioma
Raymond Huang, United States
JS06.2 Treatment standards of meningiomas- Current standard and future avenues
Matthias Preusser, Austria
JS06.3 Theranostics in meningiomas - from rationale to evidence
Nathalie Albert, Germany
Workshop (WS03) | EANO Youngsters: How to keep up with AI
Chairs: tbc
WS03.1 Artificial intelligence in histopathology
Moritz Gerstung, Germany
WS03.2 Radiomics in trials and translation into clinical routine
Spyridon Bakas, United States
17:15-18:45 hrs
Poster Pitches & Poster Viewing with authors II
19:30-23:30 hrs
EANO Evening
Contact Us
EANO Meetings | Wiener Medizinische Akademie GmbH
Alser Strasse 4 | 1090 Vienna | Austria
Tel: +43 1 405 13 83 14 | Fax: +43 1 405 13 83 914
Email: eano-meetings@eano.eu
Newsletter
Subscribe to our newsletter and stay up to date with the latest news and deals!
